Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients-Reference-Cited by-同舟云学术

Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients

Published:2023-12-20 Issue: Volume: Page:
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

Bleckman Roos F.^ORCID,Broekman K. Esther,Roets Evelyne,Mohammadi Mohammed,Desar Ingrid M. E.,Gelderblom Hans,Mathijssen Ron H. J.,Steeghs Neeltje,de Graeff Pauline,Reyners Anna K. L.

Funder

Novartis

Pfizer

Bayer

Deciphera Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

https://link.springer.com/content/pdf/10.1007/s40266-023-01084-8.pdf

Reference32 articles.

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80. https://doi.org/10.1126/science.279.5350.577.

2. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294–9. https://doi.org/10.1053/j.gastro.2004.02.021.

3. Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:923–34. https://doi.org/10.1016/S1470-2045(20)30168-6.

4. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68–78. https://doi.org/10.1093/annonc/mdy095.

5. Klug LR, Corless CL, Heinrich MC. Inhibition of KIT tyrosine kinase activity: two decades after the first approval. J Clin Oncol. 2021;39:1674–86. https://doi.org/10.1200/jco.20.03245.